Alexandria Real Estate Equities faces a confirmed technical downtrend, life-science tenant concentration representing more than half of net operating income, a 12% revenue decline, and only 3.2% upside to near-term resistance with unfavorable risk/reward — a combination that favors reducing exposure and waiting for conditions to improve.
Thesis pillars
- Tenant Concentration Churn Risk→Stable
- Death Cross Confirmed Downtrend→Stable
- Revenue Declining Twelve Percent→Stable
- +1 more pillar — see the Why tab for full reasoning
Alexandria Real Estate Equities (ARE) Stock Analysis
Real Estate · REIT - Office
Sell if holding. At $50.23, A.R:R is negative (-1.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: REIT tenant concentration cliff: 53% of NOI from investment-grade or publicly traded large cap tenants (≥40% threshold). Single-tenant churn risk dominates spot FFO.; Concentration risk — Property Type: life science.
Alexandria Real Estate Equities owns and operates 340 life science REIT properties in North America totaling approximately 39.4 million RSF, concentrated in Greater Boston, San Francisco Bay Area, San Diego, and five other U.S. innovation cluster markets. The company earns... Read more
Sell if holding. At $50.23, A.R:R is negative (-1.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: REIT tenant concentration cliff: 53% of NOI from investment-grade or publicly traded large cap tenants (≥40% threshold). Single-tenant churn risk dominates spot FFO.; Concentration risk — Property Type: life science. Chart setup: No clear chart pattern; technical signals are mixed. Score 3.9/10, high confidence.
Passes 6/10 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 28d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA) and reit tenant cliff hard block. Suitability: moderate.
About Alexandria Real Estate Equities
About Alexandria Real Estate Equities
Alexandria Real Estate Equities owns 35.9 million RSF of operating life science laboratory properties concentrated in seven U.S. innovation cluster markets, including Greater Boston, San Francisco Bay Area, and San Diego. At December 31, 2025, portfolio occupancy was 90.9%, investment-grade or publicly traded large cap tenants contributed 53% of annual rental revenue, and 3.5 million RSF of Class A/A+ properties were under construction. The company reported a total market capitalization of $20.75 billion.
Alexandria earns rental revenue primarily through triple-net leases, with approximately 92% of leases (on an annual rental revenue basis) structured as NNN arrangements that pass substantially all taxes, insurance, utilities, and operating expenses to tenants. Roughly 97% of leases contained annual rent escalations of approximately 3%, either fixed or indexed to CPI, providing contractual growth in base rent. The tenant base spans multinational pharmaceutical companies, biotechnology firms, life science product and device companies, academic research institutions, U.S. government research agencies, and venture capital firms. Properties are concentrated in seven geographic segments — Greater Boston, San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City — primarily within Megacampus environments designed for laboratory and collaborative research use. Competitors for investment opportunities include other REITs, insurance companies, pension funds, private equity entities, and foreign investors.
Show full overview
Alexandria's portfolio consists entirely of life science laboratory properties, and the 10-K explicitly flags dependence on the health of the life science industry as a material risk. Policy changes at the FDA, NIH, and SEC — or reductions in government spending and research funding — could materially affect tenants' ability to secure capital for research and development or to commercialize products, in turn impairing their ability to make rental payments. A partial or complete government shutdown could delay commercialization timelines or reduce R&D funding, exposing the portfolio to tenant financial stress beyond typical real estate credit risk.
See also: Real Estate · REIT - Office
From Alexandria Real Estate Equities's most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-07-07Recent Developments — Alexandria Real Estate Equities
Latest news
- NEWS Alexandria Real Estate Equities Inc. stock underperforms Wednesday when compared to competitors - MarketWatch — MarketWatch negative
- NEWS Unveiling Alexandria Real Estate Equities (ARE) Q1 Outlook: Wall Street Estimates for Key Metrics - Yahoo Finance — Yahoo Finance neutral
- NEWS Insider Sell: Hallie Kuhn Sells Shares of Alexandria Real Estate Equities Inc (ARE) - GuruFocus — GuruFocus negative
- NEWS Hallie Kuhn Sells 536 Shares of Alexandria Real Estate Equities (NYSE:ARE) Stock - MarketBeat — MarketBeat neutral
- NEWS Alexandria real estate EVP Hallie Kuhn sells $25,835 in stock - Investing.com — Investing.com negative
Generated 2026-07-07T12:21:42Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHPropertylife science10-K Item 1A: 'We are dependent on the health of the life science industry, and changes within this industry...may adversely impact their ability to make rental payments to us'
- HIGHTenantinvestment-grade or publicly traded large cap tenants53%10-K Item 1: 'Investment-grade or publicly traded large cap tenants represented 53% of our total annual rental revenue in effect as of December 31, 2025'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Revenue shrinking — -11.5% YoY. Growth thesis broken unless recovery story develops.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $50.23, A.R:R is negative (-1.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: REIT tenant concentration cliff: 53% of NOI from investment-grade or publicly traded large cap tenants (≥40% threshold). Single-tenant churn risk dominates spot FFO.; Concentration risk — Property Type: life science. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $46.78. Score 3.9/10, high confidence.
Take-profit target: $54.36 (+9.0% upside). Prior stop was $46.78. Stop-loss: $46.78.
REIT tenant concentration cliff: 53% of NOI from investment-grade or publicly traded large cap tenants (≥40% threshold). Single-tenant churn risk dominates spot FFO.; Concentration risk — Property Type: life science; Concentration risk — Tenant: investment-grade or publicly traded large cap tenants (53.0%).
Alexandria Real Estate Equities trades at a P/E of N/A (forward -59.8). TrendMatrix value score: 5.2/10. Verdict: Sell.
25 analysts cover ARE with a consensus score of 2.8/5. Average price target: $52.
What does Alexandria Real Estate Equities do?Alexandria Real Estate Equities owns and operates 340 life science REIT properties in North America totaling...
Alexandria Real Estate Equities owns and operates 340 life science REIT properties in North America totaling approximately 39.4 million RSF, concentrated in Greater Boston, San Francisco Bay Area, San Diego, and five other U.S. innovation cluster markets. The company earns rental income under primarily triple-net leases with pharmaceutical, biotech, and research institution tenants, with 90.9% portfolio occupancy and 53% of rental revenue from investment-grade or publicly traded large cap tenants as of December 31, 2025.